Search

everythinglearnresearchcommunity

for

Search:↓

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

The DPCP/HPβCD complex improves solubility and anti-inflammatory effects for alopecia areata treatment.

Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

Farudodstat may effectively treat alopecia areata without harming hair follicles.

Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.

Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.

Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.

Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.

Early genetic testing and JAK inhibitors can help treat systemic inflammation in SAVI patients.

Certain cytokines and growth factors can inhibit hair growth and may affect alopecia areata.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.

The study suggested certain immune cells might cause alopecia areata, but it was retracted.

Alopecia areata patients may have higher cardiovascular risk factors, so screening for metabolic syndrome components is suggested.

IL-4 and IL-13 might play a role in a type of hair loss similar to alopecia areata.

AIRE deficiency causes hair loss similar to alopecia areata in mice.

Farudodstat may effectively treat alopecia areata without harmful side effects.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Alopecia areata patients don't have increased atherosclerosis risk, but may have higher cardiovascular risk due to smoking, blood sugar, and blood pressure.

PCOS involves immune system issues and inflammation, possibly leading to autoimmune diseases.

γδTregs can protect hair follicles from alopecia areata and may help regrow hair.

Dupilumab helped a 4-year-old grow hair back after another treatment failed.

Farudodstat may effectively treat alopecia areata by protecting hair follicles without harmful effects.

Kaempferol helps skin stem cells grow and may improve skin thickness due to its 3-OH group.

Higher levels of IL-1a and IL-1RA were found in severe alopecia areata cases.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.

Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.